Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Salivary Gland Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 24Bevacizumab 21Carboplatin 20liposomal doxorubicin 15Specimen Handling 14olaparib 13Magnetic Resonance Spectroscopy 13Gemcitabine 10Topotecan 9pembrolizumab 8Biopsy 8Taxes 7Immunoglobulin G 6Disulfides 6niraparib 5Doxorubicin 5mirvetuximab soravtansine 4cediranib 4oregovomab 3Nivolumab 3Drug Therapy 3Docetaxel 3Cyclophosphamide 3Cisplatin 3sarilumab 2rucaparib 2cemiplimab 2berzosertib 2adavosertib 2Saline Solution 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × 90 days × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡